Unknown

Dataset Information

0

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.

ABSTRACT:

SUBMITTER: Correnti CE 

PROVIDER: S-EPMC5943151 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.

Correnti Colin E CE   Laszlo George S GS   de van der Schueren Willem J WJ   Godwin Colin D CD   Bandaranayake Ashok A   Busch Melanie A MA   Gudgeon Chelsea J CJ   Bates Olivia M OM   Olson James M JM   Mehlin Christopher C   Walter Roland B RB  

Leukemia 20180131 5

Similar Datasets

Unknown Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy.
| S-EPMC10475457 | biostudies-literature
Unknown Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
| S-EPMC4558758 | biostudies-literature
Unknown Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies.
| S-EPMC11674949 | biostudies-literature
Unknown Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.
| S-EPMC4492699 | biostudies-literature
Unknown Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
| S-EPMC9007942 | biostudies-literature
Unknown Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
| S-EPMC4797019 | biostudies-literature
Unknown GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
| S-EPMC7731630 | biostudies-literature
Unknown CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
| S-EPMC6217777 | biostudies-literature
Unknown A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies.
| S-EPMC11876962 | biostudies-literature
Unknown Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
| S-EPMC10324450 | biostudies-literature